Wire · operational-macro
FDA clears phase 1/2 trial of androgen receptor antagonist in mCRPC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The FDA has cleared an Investigational New Drug application for EIK1006, enabling a first-in-human phase 1/2 trial targeting metastatic androgen pathway modulation-resistant prostate cancer. EIK1006 is designed to inhibit both wild-type androgen receptors and resistant variants, with patient dosing expected to start in 2027.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You have a clearer regulatory path to launch new prostate cancer therapies targeting resistant androgen receptors. Prepare to accelerate patient recruitment and partnerships for your clinical studies starting next year.
◆ Coverage
1 source · 17 Nov 2026
◆ Related on Wire
◆ Topics